Advice
Following a full submission
paliperidone (Invega®) is not recommended for use within NHS Scotland for the treatment of schizophrenia.
Paliperidone has been shown to be superior to placebo in reducing symptoms of schizophrenia. However, there are limited statistical comparative data versus other atypical antipsychotics.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice105KB (PDF)
Medicine details
- Medicine name:
- paliperidone prolonged-release tablets (INVEGA)
- SMC ID:
- 453/08
- Indication:
- Treatment of schizophrenia
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 April 2008